Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

Cheng, Ann-Lii

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. [electronic resource] - Journal of hepatology 02 2020 - 307-319 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

1600-0641

10.1016/j.jhep.2019.09.025 doi


Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Antineoplastic Agents, Immunological--therapeutic use
B7-H1 Antigen--antagonists & inhibitors
Biomarkers, Tumor--blood
CTLA-4 Antigen--antagonists & inhibitors
Carcinoma, Hepatocellular--blood
Combined Modality Therapy--methods
Humans
Immune Checkpoint Inhibitors--pharmacology
Immunotherapy--methods
Liver Neoplasms--blood
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Progression-Free Survival
T-Lymphocytes--immunology